Jesse Armin Kaplan, a Director, acquired 193,000 Common Shares on a direct ownership basis at prices ranging from $0.500 to $0.530 between December 2nd, 2021 and December 3rd, 2021. The insider also acquired 30,000 Common Shares on an indirect ownership basis for registered holder Plaza Capital Advisors at a price of $0.550 on December 2nd, 2021. This represents a $115,330 investment into the company's shares and an account share holdings change of 10.4%.
Yisroel Weinreb, a Director, acquired 200,000 Common Shares on an indirect ownership basis for registered holder Bay Street Mercantile Inc. at prices ranging from $0.510 to $0.530 between December 2nd, 2021 and December 3rd, 2021. This represents a $102,750 investment into the company's shares and an account share holdings change of 6.9%.
Yaron Conforti, CEO and Director, acquired 97,600 Common Shares on a direct ownership basis at prices ranging from $0.510 to $0.580 between December 1st, 2021 and December 3rd, 2021. This represents a $55,208 investment into the company's shares and an account share holdings change of 2.9%.
Novamind is in the Healthcare Facilities & Services Sub Industry Group under the Healthcare Sector.
Novamind Inc. is a Canada-based mental health company. The Company enables safe access to psychedelic medicine through a network of psychiatry clinics, and clinical research sites. It provides mental health services through its subsidiary, Cedar Psychiatry Inc. (Cedar Psychiatry) and provides clinical trial services through its other subsidiary, Cedar Clinical Research Inc. (CCR). Cedar Psychiatry offers psychotherapy, psychiatric medication management, transcranial magnetic stimulation (TMS) and ketamine-assisted psychotherapy. CCR specializes in hosting Phase I to Phase IV clinical trials and its research is focused on emerging treatment options in neuropsychiatry on behalf of third-party sponsors. CCR operates a research center in Springville, Utah, which provides select contract research organization (CRO) services for pharmaceutical companies. CCR is also developing psychedelic-assisted psychotherapy treatment protocols to provide patients with evidence-based therapies.
No Comments